🎉 M&A multiples are live!
Check it out!

S Biomedics Valuation Multiples

Discover revenue and EBITDA valuation multiples for S Biomedics and similar public comparables like Mesoblast, Cynata Therapeutics, and Aroa Biosurgery.

S Biomedics Overview

About S Biomedics

S Biomedics Co Ltd researches and develops cell therapies for regenerative biomedicine. It owns two platform technologies: Functionally Enhanced Cell Spheroid and Targeted Embryonic Stem Cell Differentiation for developing cell therapy products that overcome the limitations of existing cell therapy products.


Founded

2005

HQ

South Korea
Employees

n/a

Website

sbiomedics.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$167M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

S Biomedics Financials

S Biomedics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, S Biomedics achieved revenue of $9.4M and an EBITDA of -$2.2M.

S Biomedics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See S Biomedics valuation multiples based on analyst estimates

S Biomedics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $8.9M $9.4M XXX XXX XXX
Gross Profit $4.2M $4.5M XXX XXX XXX
Gross Margin 47% 48% XXX XXX XXX
EBITDA -$2.7M -$2.2M XXX XXX XXX
EBITDA Margin -30% -24% XXX XXX XXX
Net Profit -$4.3M -$5.1M XXX XXX XXX
Net Margin -48% -55% XXX XXX XXX
Net Debt $6.2M $6.1M XXX XXX XXX

Financial data powered by Morningstar, Inc.

S Biomedics Stock Performance

As of April 15, 2025, S Biomedics's stock price is KRW 21350 (or $15).

S Biomedics has current market cap of KRW 251B (or $171M), and EV of KRW 246B (or $167M).

See S Biomedics trading valuation data

S Biomedics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$167M $171M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

S Biomedics Valuation Multiples

As of April 15, 2025, S Biomedics has market cap of $171M and EV of $167M.

S Biomedics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate S Biomedics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for S Biomedics and 10K+ public comps

S Biomedics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $167M XXX XXX XXX
EV/Revenue 17.9x XXX XXX XXX
EV/EBITDA -75.9x XXX XXX XXX
P/E -37.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -47.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get S Biomedics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

S Biomedics Valuation Multiples

S Biomedics's NTM/LTM revenue growth is n/a

S Biomedics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, S Biomedics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate S Biomedics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for S Biomedics and other 10K+ public comps

S Biomedics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 5% XXX XXX XXX XXX
EBITDA Margin -24% XXX XXX XXX XXX
EBITDA Growth -17% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue 9% XXX XXX XXX XXX
G&A Expenses to Revenue 12% XXX XXX XXX XXX
R&D Expenses to Revenue 43% XXX XXX XXX XXX
Opex to Revenue 88% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

S Biomedics Public Comps

See public comps and valuation multiples for Regenerative Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Lineage Cell Therapeutics XXX XXX XXX XXX XXX XXX
Arovella Therapeutics XXX XXX XXX XXX XXX XXX
Aroa Biosurgery XXX XXX XXX XXX XXX XXX
Cynata Therapeutics XXX XXX XXX XXX XXX XXX
Mesoblast XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

S Biomedics M&A and Investment Activity

S Biomedics acquired  XXX companies to date.

Last acquisition by S Biomedics was  XXXXXXXX, XXXXX XXXXX XXXXXX . S Biomedics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by S Biomedics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About S Biomedics

When was S Biomedics founded? S Biomedics was founded in 2005.
Where is S Biomedics headquartered? S Biomedics is headquartered in South Korea.
Is S Biomedics publicy listed? Yes, S Biomedics is a public company listed on KRX.
What is the stock symbol of S Biomedics? S Biomedics trades under 304360 ticker.
When did S Biomedics go public? S Biomedics went public in 2023.
Who are competitors of S Biomedics? Similar companies to S Biomedics include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics.
What is the current market cap of S Biomedics? S Biomedics's current market cap is $171M
What is the current revenue growth of S Biomedics? S Biomedics revenue growth between 2023 and 2024 was 5%.
Is S Biomedics profitable? Yes, S Biomedics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.